Merck puts money on Arcoxia
Executive Summary
Merck raises 2007 earnings guidance on the assumption that Arcoxia (etoricoxib), its follow-on product to the withdrawn arthritis medication Vioxx, will be approved by FDA, the company announces Dec. 6. The Arcoxia NDA has a user fee action date in April 2007 following Merck's submission of a response to FDA's November 2004 "approvable" letter (1"The Pink Sheet" Nov. 13, 2006, In Brief). The submission limits the proposed indication for the COX-2 inhibitor, which has been approvable since October 2004, to osteoarthritis. Merck anticipates that 2007 earnings per share will be in the range of $2.36 to $2.49. "Other sales," which includes products Arcoxia, Januvia and Proscar among many others, is expected to be between $5.2 billion and $5.6 bil...You may also be interested in...
Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Teva’s Austedo Fails In Tourette’s Syndrome
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: